Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases.

ABSTRACT:

Objective

Vaccination decreases the risk of severe COVID-19 but its impact on postacute sequelae of COVID-19 (PASC) is unclear among patients with systemic autoimmune rheumatic diseases (SARDs) who may have blunted vaccine immunogenicity and be vulnerable to PASC.

Methods

We prospectively enrolled patients with SARD from a large healthcare system who survived acute infection to complete surveys. The symptom-free duration and the odds of PASC (any symptom lasting ≥28 or 90 days) were evaluated using restricted mean survival time and multivariable logistic regression, respectively, among those with and without breakthrough infection (≥14 days after initial vaccine series).

Results

Among 280 patients (11% unvaccinated; 48% partially vaccinated; 41% fully vaccinated), the

SUBMITTER: Patel NJ 

PROVIDER: S-EPMC10225013 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature